Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU.

Background: Increased toxicities have been identified with higher doses of pegaspargase (PEG-ASP) in adults. This has led to routine use of a dose cap of 3,750 IU for adult acute lymphoblastic leukemia (ALL) patients in most institutions. In pediatric ALL patients, PEG-ASP is not capped.

Gerontology and geriatric issues and trends in U.S. nursing programs: a national survey.

Elderly persons in the United States constitute an increasing proportion of our population impacting nursing education. The purpose of this study was to survey geriatric and gerontology issues and trends in U.S.